Biologic drugs, including those used for the treatment of cancer, are currently manufactured using processes that are not only time-consuming but also extremely expensive. Our work aims to reduce these resource burdens through the development of novel strategies and innovative platforms that enable rapid flexible production of protein therapeutics.
Currently, we are involved in the following:
- Developing a biomanufacturing platform designed to achieve on-demand production of a single dose of drug substance within 24 hours. This project is funded as part of the DARPA Bio-MOD program.
- Developing an expression pipeline for the rapid production of full-length monoclonal antibodies isolated from high-throughput screens. The Bill and Melinda Gates Foundation, the Collaboration for AIDS Vaccine Discovery (CAVD), and the W.M. Keck Foundation fund this work.